Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacitidine 5-Day Schedule in Low-Risk MDS
NCT00897130Phase 2Completed
- Sponsor
- University of Brescia
- Start
- Aug 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by University of Brescia. Primary endpoints: Hematologic Response at 36 months and Toxicity at 36 months. Started Aug 2008; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00897130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00897130.